Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines

Anti-Cancer Drug Design

Volumn 16, Issue 6, 2001, Pages 305-315

  Rothenborg Jensen, Line ^a   Hansen, Henrik F ^a   Wessel, Irene ^a   Nitiss, John L ^a   Schmidt, Günther ^a   Jensen, Peter Buhl ^a   Sehested, Maxwell ^a   Jensen, Lars H ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Anti cancer drug; DNA cleavage; Etoposide; MDR circumvention; Podophyllotoxin conjungates; Topoisomerase II

Indexed keywords

4' NOREPIPODOPHYLLOTOXIN; 4BETA [6 (9 ACRIDINYLAMINO)OCTANOYLAMIDO] 4 DEOXY 4 DEMETHYLPODOPHYLLOTOXIN; 4BETA [8 (9 ACRIDINYLAMINO)OCTANOYLAMIDO] 4 DEOXY 4 DEMETHYLPODOPHYLLOTOXIN; ACLARUBICIN; ACRIDINE DERIVATIVE; AMIDE; AMSACRINE; CAMPTOTHECIN; CISPLATIN; CYTARABINE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIPODOPHYLLOTOXIN; ETOPOSIDE; GYRASE INHIBITOR; MITOXANTRONE; N 6 AMINOHEXANYLAMIDE; N 8 AMINOOCTANYLAMIDE; PODOPHYLLOTOXIN; RAZOXANE; TENIPOSIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA DAMAGE; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ACLARUBICIN; ACRIDINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CELL SURVIVAL; CROSS-LINKING REAGENTS; DNA; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; PODOPHYLLOTOXIN; POLYMERASE CHAIN REACTION; RAZOXANE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

MURINAE; STAPHYLOCOCCUS PHAGE 187;

EID: 0035759195     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Anyanwutaku I.O., Guo X., Chen H.-X., Ji Z., Lee K.-H., Cheng Y.-C. (1996) Activities of novel nonglycosidic epipodophyllotoxins in etoposide-sensitive and -resistant variants of human KB cells, p-88 cells, and in vivo multidrug-resistant murine leukemia cells. Molecular Pharmacology, 49, 721.
2. Arimondo P., Boukarim C., Bailly C., Dauzonne D., Monneret C. (2000) Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anti-cancer Drug Design, 15, 413.
3. Austin C.A., Marsh K.L. (1998) Eukaryotic DNA topoisomerase II beta. Bioessays, 20, 215.
4. Brock I., Hipfner D.R., Nielsen B.S., Jensen P.B., Deeley R.G., Cole S.P. Sehested M. (1995) Sequential co-expression of the multidrug resistance genes MRP and Mdrl and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Research, 55, 459.
5. Campling B.G., Young L.C., Baer K.A., Lam Y.M., Deeley R.G., Cole S.P., Gerlach J.H. (1997) Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clinical Cancer Research 3, 115.
6. Carney D.N., Gazdar A.F., Bepler G., Guccion J.G., Marangos P.J., Moody T.W., Zweig M.H., Minna J.D. (1985) Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Research, 45, 2913.
7. Chen A.Y., Liu L.F. (1994) DNA topoisomerases: essential enzymes and lethal targets. Annual Review of Pharmacology and Toxicology, 34, 191.
8. Dean M., Rzhetsky A., Allikmets R. (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Research, 11, 1156.
9. de Leij L., Postmus P.E., Buys C.H., Elema J.D., Ramaekers F., Poppema S., Brouwer M., van der Veen A.Y., Mesander G., The T.H. (1985) Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Research, 45, 6024.
10. Dereuddre S., Delaporte C., Jacquemin-Sablon A. (1997) Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors. Cancer Research, 57, 4301.
11. Falck J., Jensen P.B., Sehested M. (1999) Evidence for repressional role of an inverted CCAAT box in cell cycle-dependent transcription of the human DNA topo isomerase IIalpha gene. Journal of Biological Chemistry, 274, 18753.
12. Friche E., Danks M.K., Schmidt C.A., Beck W.T. (1991) Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Research, 51, 4213.
13. Gao H., Huang K.C., Yamasaki E.F., Chan K., Chohan L., Snapka R.M. (1999) XK469, a selective topoisomerase IIbeta poison. Proceedings of the National Academy of Sciences. USA, 96, 12168.
14. Grue P., Grasser A., Sehested M., Jensen P.B., Uhse A., Straub T., Ness W., Boege F. (1998) Essential mitotic functions of DNA topoisomerase Ilalpha are not adopted by topoisomerase IIbeta in human H69 cells. Journal of Biological Chemistry, 273, 33660.
15. Hansen H.F., Jensen R.B., Willumsen A.M., Norskov-Lauritsen N., Ebbesen P., Nielsen P.E., Buchardt O. (1993) New compounds related to podophyllotoxin and congeners: synthesis, structure elucidation and biological testing. Acta Chemica Scandinavica, 47, 1190.
16. Jensen P.B., Vindelov L., Roed H., Demant E.J., Sehested M., Skovsgaard T., Hansen H.H. (1989) In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). British Journal of Cancer, 60, 838.
17. Jensen P.B., Sorensen B.S., Demant E.J., Sehested M., Jensen P.S., Vindelov L., Hansen H.H. (1990) Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Research, 50, 3311.
18. Jensen P.B., Jensen P.S., Demant E.J., Friche E., Sorensen B.S., Sehested M., Wassermann K., Vindelov L., Westergaard O., Hansen H.H. (1991) Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Research, 51, 5093.
19. Jensen P.B., Christensen I.J., Sehested M., Hansen H.H., Vindelov L. (1993a) Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. British Journal of Cancer, 67, 311.
20. Jensen P.B., Sorensen B.S., Sehested M., Demant E.J., Kjeldsen E., Friche E., Hansen H.H. (1993b) Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. Biochemical Pharmacology, 45, 2025.
21. Jensen P.B., Holm B., Sorensen M., Christensen I.J., Sehested M. (1997) In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. British Journal of Cancer, 75, 869.
22. Kohn K.W., Erickson L.C., Ewig R.A., Friedman C.A. (1976) Fractionation of DNA from mammalian cells by alkaline elution. Biochemistry, 15, 4629.
23. Litman T., Druley T.E., Stein W.D., Bates S.E. (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cellular and Molecular Life Sciences, 58, 931.
24. Liu L.F. (1989) DNA topoisomerase poisons as antitumor drugs. Annual Review of Biochemistry, 58, 351.
25. Mao Y., Yu C., Hsieh T.S., Nitiss J.L., Liu A.A., Wang H., Liu L.F. (1999) Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. Biochemistry, 38, 10793.
26. Mirski S.E., Sparks K.E., Yu Q., Lang A.J., Jain N., Campling B.G., Cole S.P. (2000) A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34. International Journal of Cancer, 85, 534.
27. Nitiss JL (1994) Roles of DNA topoisomerases in chromosomal replication and segregation. Advances in Pharmacology, 29A, 103.
28. Nitiss J.L., Zhou J., Rose A., Hsiung Y., Gale K.C., Osheroff N. (1998) The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II. Biochemistry, 37, 3078.
29. Perrin D., van Hille B., Hill B.T. (1998) Differential sensitivities of recombinant human topoisomerase IIalpha and beta to various classes of topoisomerase II-interacting agents. Biochemical Pharmacology, 56, 503.
30. Roca J., Wang J.C. (1992) The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases. Cell, 71, 833.
31. Roca J., Wang J.C. (1994) DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell, 77, 609.
32. Sehested M., Wessel I., Jensen L.H., Holm B., Oliveri R.S., Kenwrick S., Creighton A.M, Nitiss J.L., Jensen P.B. (1998) Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Research, 58, 1460.
33. Skovsgaard T. (1978) Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Research, 38, 1785.
34. Tsutsui K., Tsutsui K., Sano K., Kikuchi A., Tokunaga A. (2001) Involvement of DNA topoisomerase IIbeta in neuronal differentiation. Journal of Biological Chemistry, 276, 5769.
35. Ueda K., Taguchi Y., Morishima M. (1997) How does P-glycoprotein recognize its substrates? Seminars in Cancer Biology, 8, 151.
36. Wang J.C. (1996) DNA topoisomerases. Annual Review of Biochemistry, 65, 635.
37. Wang J.C., Caron P.R., Kim R.A. (1990) The role of DNA topoisomerases in recombination and genome stability: a double-edged sword? Cell, 62, 403.
38. Wessel I., Jensen L.H., Jensen P.B., Falck J., Rose A., Roerth M., Nitiss J.L., Sehested M. (1999) Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform. Cancer Research, 59, 3442.
39. Yang X., Li W., Prescott E.D., Burden S.J., Wang J.C. (2000) DNA topoisomerase IIbeta and neural development. Science, 287, 131.